瑞桥鼎科集团与Pulmonx达成独家战略合作

公司动态

2024.06.01

139

2024年6月1日，瑞桥鼎科（上海）医疗科技有限公司（以下简称“瑞桥鼎科集团”）与肺通国际有限责任公司（以下简称“Pulmonx”，Nasdaq股票代码: LUNG）宣布达成战略合作。

On Jun 1st, 2024, EverBridge (Shanghai) Medical Co., Ltd., ("EverBridge Group") and Pulmonx Corporation (" Pulmonx ", NASDAQ: LUNG) announced a strategic collaboration.

根据协议条款，瑞桥鼎科集团将成为Zephyr®支气管活瓣、Chartis®肺部评估系统及相关产品在大中华区的独家总经销商，负责该产品的销售和推广工作。未来，双方将携手努力，共同快速推动上述产品在大中华区的市场拓展，为广大慢性阻塞性肺病（COPD）患者带来福音。

Under the terms of the agreement, EverBridge Group will be responsible for the sales and promotion of the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and relevant products as the exclusive distributor in Greater China. The two parties will collaborate to accelerate the market expansion of these products, benefiting patients with chronic obstructive pulmonary disease (COPD).

同时，我们将积极探索更广泛和深入的合作领域和模式，持续以互惠互利为基石，共同推进战略合作向更高层次发展，以科技创新赋能医疗事业，造福中国和全球的医生和患者。

Additionally, Everbridge will continue to explore broader and deeper opportunities, to empower the medical industry through scientific and technological innovation, benefiting physicians and patients in China and globally.

此次战略合作是瑞桥鼎科集团业务布局中的一个重要决策。通过与Pulmonx合作，瑞桥鼎科集团将进一步深化与相关领域医生与患者的联系，建立更稳固的合作关系，精准地把握医患需求，为患者提供更卓越的产品与健康福祉。

This strategic partnership represents a significant step for EverBridge Group. By partnering with Pulmonx, EverBridge Group aims to strengthen the connection with the physicians and patients in related fields, establish a robust cooperative relationship, accurately address the needs of healthcare professionals and patients, and deliver superior products to enhance health and well-being.

【END】

关于瑞桥鼎科集团

EverBridge Group

瑞桥鼎科集团是一家亚洲领先的医疗科技集团，致力于为全球客户提供尖端的高品质的和可负担的医疗技术，快速增长的产品组合涵盖外周血管神经科学和肿瘤三大领域，并依托五大专业研发和精益生产中心，在球囊、导管、支架、表面处理和有源设备领域提供一流的OEM/ODM服务。

我们与来自全球的优秀企业开展广泛合作，为亚洲和世界的医疗科技创新搭建桥梁，为全球的医生和患者提供更好的治疗选择。

EverBridge Group is a leading MedTech company in Asia, committed to providing high-quality and affordable products to global customers.

We engage in extensive collaboration with outstanding companies around the world, establishing a bridge for medical technology innovation between Asia and the world, and providing better treatment options for doctors and patients worldwide.

关于肺通国际

Pulmonx

Pulmonx是慢性阻塞性肺病 (COPD) 微创治疗领域的全球领导者，其Zephyr®支气管活瓣、Chartis® 肺部评估系统和 StratX® 肺部分析平台旨在评估和治疗经医疗管理但仍有严重肺气肿的COPD患者。Zephyr 支气管活瓣于 2018 年 6 月被美国FDA批准为“突破性器械”。

Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” (The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines.)

瑞桥鼎科集团与Pulmonx达成独家战略合作

推荐阅读